Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Autoregulation of Blood Flow01:17

Autoregulation of Blood Flow

Autoregulation mechanisms are characterized by their inherent capacity for self-regulation without necessitating specific nervous stimulation or endocrine control. These mechanisms facilitate the adjustment of blood flow and, therefore, perfusion specific to each tissue region. This self-regulation encompasses chemical signals and myogenic controls.
Chemical Signaling in Autoregulation
Chemical signaling operates at the precapillary sphincter level, inciting either contraction or relaxation.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gene-Dosage Effect of V89L Variants in Steroid 5α-Reductase Type 2 and Increased Risk of 46, XY Disorders of Sex Development: A Systematic Review and Meta-Analysis.

Journal of Indian Association of Pediatric Surgeons·2026
Same author

Surgical Insights and Therapeutic Challenges in the Management of Giant Complex Vascular Malformation of the Buttock.

Journal of Indian Association of Pediatric Surgeons·2026
Same author

Clinical Utility of Infrared Thermography in Pediatric Patients: A Systematic Review of Surgical and Nonsurgical Applications.

Journal of Indian Association of Pediatric Surgeons·2026
Same author

Expanding the Genetic Blueprint of Wilms Tumor: An Account of 71 Novel Variants across 16 Genes with Novel Implications for Wilms Tumor Pathogenesis.

Journal of Indian Association of Pediatric Surgeons·2026
Same author

Variations in the Level of Termination and Characteristics of Tracheoesophageal Fistula in Patients with Type C Esophageal Atresia.

Journal of Indian Association of Pediatric Surgeons·2026
Same author

Implementation of enhanced recovery after surgery (ERAS) protocols for paediatric laparoscopic surgery: a single-center experience.

Pediatric surgery international·2026

Related Experiment Videos

Variable response to propranolol therapy for infantile hemangiomas.

Vishesh Jain1, Subhasis Roychoudhury, Rajiv Chadha

  • 1Department of Pediatric Surgery, Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi, India.

Indian Journal of Dermatology
|May 23, 2012
PubMed
Summary

Propranolol effectively treats infantile hemangiomas, leading to lesion involution. However, responses vary, with one infant showing minimal initial improvement and lesion growth.

Keywords:
Propranololinfantile hemangiomasvascular anomaly

Related Experiment Videos

Area of Science:

  • Pediatric Dermatology
  • Vascular Lesions
  • Pharmacology

Background:

  • Hemangiomas are common pediatric vascular tumors.
  • Propranolol's efficacy in treating hemangiomas was discovered serendipitously.
  • Clinical use of propranolol for hemangiomas is increasing due to favorable responses.

Purpose of the Study:

  • To present clinical experience with propranolol treatment for infantile hemangiomas.
  • To evaluate the response rates of propranolol in a small cohort of infants.

Main Methods:

  • Retrospective case review of three infants with hemangiomas treated with propranolol.
  • Clinical assessment of lesion response to propranolol therapy.

Main Results:

  • One infant experienced marked involution of the hemangioma.
  • A second infant showed an appreciable positive response to propranolol.
  • The third infant had a minimal initial response with subsequent lesion enlargement.

Conclusions:

  • Propranolol is a promising treatment for infantile hemangiomas.
  • Treatment outcomes with propranolol can be variable.
  • Further research is needed to optimize propranolol therapy for hemangiomas.